A range of benefits and concerns have been raised regarding the availability of genomic testing for direct purchase and use by consumers. These apply to all types of genomic tests, but are arguably most acute for tests used for medically-related purposes. Despite concerns around direct-to-consumer tests existing for many years, evidence of harm has mostly not been systematically collected and is limited. As direct-to-consumer genomic testing becomes more widespread and covers a greater variety of conditions, evidence of positive impacts and harms may grow. We have heard calls for updated regulation of direct-to-consumer genomic testing. While the Government has acknowledged the importance of maintaining public trust in genomics and said that it would “establish a gold standard UK model for how to apply strong and consistent ethical and regulatory standards”, it has committed only to consulting on and publishing future regulations for Great Britain at a “later date”. The Government should set out a specific timeframe in which it intends to review the case for introducing new regulations for genomic tests provided directly to consumers (‘direct-to-consumer genomic tests’). (Paragraph 34) Supporting a responsible direct-to-consumer genomic testing industry